Drug Profile
MSH fusion toxin
Alternative Names: DAB389 MSHLatest Information Update: 07 Feb 2001
Price :
$50
*
At a glance
- Originator Seragen
- Class Antineoplastics
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 07 Feb 2001 Discontinued-Preclinical for Malignant melanoma in USA (Unknown route)